Recent insider trends for Biocept, Inc. (NASDAQ:BIOC) have caught the attention of investors. Analysts monitor insider data to understand the sentiment of a company’s largest and most important shareholders. BIOC’s insider trading patterns have some implications for where the stock might be headed.
Institutions own 07.93% of Biocept, Inc. (BIOC)’s shares. The total value of these holdings, in millions, is $3. Among active positions in the latest quarter, 10 holders increased their positions by a total of 333011 shares, 6 holders decreased the positions by a total of 27558 shares, and 7 holders held their positions. This works out to a net increase in ownership of 305453 shares, and suggests that institutions are feeling bullish about the stock.
Among new and sold out positions, 4 holders initiated new positions by a total of 45407 shares and 1 holders exited their positions by a total of 3400 shares. This nets out to an increase of 42007 shares and is a bullish sign for BIOC.
Insider ownership increased by a total of 0 shares, which suggests that BIOC’s key executives are feeling more optimistic about the outlook for the stock. The data from the past twelve months tells a different story: insiders executed 4 buys and 3 sells, and ownership decreased by a net of 1.56 million shares.
Comparing the number of shares sold short over time is a method analysts often use to get a reading on investor sentiment. Biocept, Inc. (NASDAQ:BIOC)’s short interest is 2.63 million shares, or 13.96% of the float. This represents an increase of 4% in the number of shares being shorted compared to the previous reading, and implies that investors felt more pessimistic about the stock during the past two weeks.
Given what the insider ownership patterns are saying, it makes sense to consider the technicals to see if these pieces of information reach the same conclusion about the outlook for BIOC. A composite of 13 technical indicators that includes measures such as moving averages and momentum oscillators suggests that BIOC is a Weak sell, which implies that BIOC is expected to underperform the market based on prior trading patterns.
Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bullish. Technical indicators (also) suggest that Biocept, Inc. (NASDAQ:BIOC) is overvalued.